---
title: "Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291290809.md"
description: "Artelo Biosciences presented evidence at ICRS 2026 linking its FABP5 inhibitor platform to lipid signaling. A multi-omics study identified linoleic acid as a key fatty acid regulated by ART26.12, highlighting its role in cellular functions and the protein's impact on linoleic acid levels."
datetime: "2026-06-30T12:59:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291290809.md)
  - [en](https://longbridge.com/en/news/291290809.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291290809.md)
generator: "portal-rs"
---

# Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026

A recent study using multi-omics analyses has pinpointed linoleic acid as a vital fatty acid that is influenced by the regulator protein ART26.12. This research delved into various biological data sets to reveal the importance of linoleic acid, highlighting its critical role in cellular functions. The findings underscore the significance of ART26.12 in modulating the levels and effects of linoleic acid within the body. This study sheds light on the relationship between ART26.12 and linoleic acid, providing valuable insights into their interconnected functions.

### Related Stocks

- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)

## Related News & Research

- [Gentian Diagnostics to attend PReS meeting, spotlight circulating calprotectin testing in pediatric rheumatology](https://longbridge.com/en/news/297638164.md)
- [Top Omeros Executive Makes Eye-Catching Move With Insider Stock Sale](https://longbridge.com/en/news/297721007.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)
- [Abbisko unit Abbisko Therapeutics doses first patient in Phase I trial of pan-KRAS inhibitor ABSK211](https://longbridge.com/en/news/297476007.md)
- [FDA Clears First Targeted Dermatomyositis Treatment From Roivant](https://longbridge.com/en/news/297552522.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**